The importance of primary tumor origin and tumor burden as measured with the peritoneal cancer index (PCI) has been clearly demonstrated in previous studies.3–5 Molecular markers such as KRAS and BRAF mutations have been used as predictive tools for optimizing antibody treatment with epidermal growth factor receptor (EGFR) blockers, and targeted therapies against BRAF mutated tumors have been used in advanced melanoma and lung cancer treatments. This evidence concerns the gene BRAF and neoplasm.